WALDENSTRÖM MACROGLOBULINEMIA
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. The approach uses low-dose chemo and radiation before a donor stem cell infusion, followed by drugs to prevent graft-versus-host disease. The goal was to control the cancer…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
New combo shows promise against tough lymphomas
Disease control CompletedThis study tested a combination of the drug lenalidomide with standard chemotherapy (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the safest dose and see how well the treatment controls the cancer. Results help doctors unders…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 26, 2026 09:01 UTC
-
New study compares drug combos for rare blood cancer
Disease control CompletedThis study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see which combination works better at controlling the disease and improving survival without progression. Participants received …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 08:56 UTC
-
New combo aims to shorten treatment for rare blood cancer
Disease control CompletedThis study tested a combination of three drugs (zanubrutinib, ixazomib, and dexamethasone) in 25 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The treatment was given for up to 24 months and then stopped, aiming to achieve deep remission without …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the drugs worked together. Researchers measured side effects and tumor…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Stem cell transplant may boost survival in rare blood cancer
Disease control CompletedThis study looked at whether a stem cell transplant (using a patient's own cells) could help people with a high-risk form of Waldenström macroglobulinemia live longer compared to standard chemotherapy. About 70 adults aged 18 to 70 with this rare blood cancer took part. The main …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New oral combo shows promise for rare blood cancer
Disease control CompletedThis study tested a three-drug oral regimen (thalidomide, cyclophosphamide, and dexamethasone) followed by maintenance therapy (thalidomide and prednisone) in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the treat…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 18, 2026 12:12 UTC